SR-BI and Antiviral Treatment Response in HCV

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The scavenger receptor type B class I (SR-BI) is a receptor for high-density lipoproteins (HDL) and one of entry factors for hepatitis C virus (HCV). The investigators aimed to examine the association of single nucleotide polymorphisms (SNPs) of the SCARB1 gene, which encodes SR-BI, with virologic responses to pegylated interferon-based treatment in Asian chronic hepatitis C (CHC) patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
• Treatments: Antiviral Agents; Interferon-alpha; Peginterferon alfa-2a

Criteria

Inclusion Criteria:

1. Naive to IFN treatment and other experimental antiviral or immunosuppressive therapy before enrollment.

2. Serum alanine aminotransferase levels, at least, twice the upper limit of normal on two occasions within the previous 6 months.

Exclusion Criteria:

1. Positive for hepatitis B surface antigen

2. Positive for human immunodeficiency virus antibody

3. Had a known history or evidence of autoimmune liver disease, inheritable disorders, renal insufficiency, malignancy

4. Had a history of daily alcohol consumption greater than 20 gram or active drug abuse.